IDEAYA Biosciences Stock Forecast, Price & News

+0.92 (+3.55 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.86 million shs
Average Volume301,003 shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IDYA News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDEAYA Biosciences logo

About IDEAYA Biosciences

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.93 out of 5 stars

Medical Sector

635th out of 1,350 stocks

Pharmaceutical Preparations Industry

308th out of 664 stocks

Analyst Opinion: 2.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

IDEAYA Biosciences (NASDAQ:IDYA) Frequently Asked Questions

Is IDEAYA Biosciences a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDEAYA Biosciences stock.
View analyst ratings for IDEAYA Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than IDEAYA Biosciences?

Wall Street analysts have given IDEAYA Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IDEAYA Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is IDEAYA Biosciences' next earnings date?

IDEAYA Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for IDEAYA Biosciences

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its quarterly earnings data on Monday, August, 9th. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.26. The business earned $8.76 million during the quarter, compared to analyst estimates of $10.04 million. IDEAYA Biosciences had a negative net margin of 84.49% and a negative trailing twelve-month return on equity of 13.85%.
View IDEAYA Biosciences' earnings history

How has IDEAYA Biosciences' stock been impacted by Coronavirus?

IDEAYA Biosciences' stock was trading at $4.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IDYA shares have increased by 453.8% and is now trading at $26.86.
View which stocks have been most impacted by COVID-19

What price target have analysts set for IDYA?

6 brokers have issued 1 year price targets for IDEAYA Biosciences' stock. Their forecasts range from $28.00 to $38.00. On average, they expect IDEAYA Biosciences' stock price to reach $32.43 in the next year. This suggests a possible upside of 20.7% from the stock's current price.
View analysts' price targets for IDEAYA Biosciences
or view top-rated stocks among Wall Street analysts.

Who are IDEAYA Biosciences' key executives?

IDEAYA Biosciences' management team includes the following people:
  • Yujiro S. Hata, President, Chief Executive Officer & Director
  • Paul A. Stone, Chief Financial Officer & Executive Vice President
  • Michael P. Dillon, Chief Scientific Officer, SVP & Head-Research (LinkedIn Profile)
  • Matthew Maurer, VP, Head-Medical Affairs & Clinical Oncology
  • Mark Lackner, SVP, Head-Biology & Translational Sciences

Who are some of IDEAYA Biosciences' key competitors?

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), The Boeing (BA), Xeris Pharmaceuticals (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?

(IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

What is IDEAYA Biosciences' stock symbol?

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include RTW Investments LP (8.51%), BlackRock Inc. (7.91%), Federated Hermes Inc. (4.26%), Price T Rowe Associates Inc. MD (3.41%), Vanguard Group Inc. (3.25%) and Point72 Asset Management L.P. (1.80%). Company insiders that own IDEAYA Biosciences stock include Bvf Partners L P/Il, Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends for IDEAYA Biosciences

Which institutional investors are selling IDEAYA Biosciences stock?

IDYA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Woodline Partners LP, EAM Global Investors LLC, EAM Investors LLC, JPMorgan Chase & Co., AQR Capital Management LLC, BNP Paribas Arbitrage SA, and Cubist Systematic Strategies LLC. Company insiders that have sold IDEAYA Biosciences company stock in the last year include Jason Throne, Mark Lackner, Michael P Dillon, Paul A Stone, and Ventures Iv LP 5Am.
View insider buying and selling activity for IDEAYA Biosciences
or view top insider-selling stocks.

Which institutional investors are buying IDEAYA Biosciences stock?

IDYA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., RTW Investments LP, Price T Rowe Associates Inc. MD, AXA S.A., Vanguard Group Inc., Sphera Funds Management LTD., Federated Hermes Inc., and State Street Corp. Company insiders that have bought IDEAYA Biosciences stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for IDEAYA Biosciences
or or view top insider-buying stocks.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEAYA Biosciences' stock price today?

One share of IDYA stock can currently be purchased for approximately $26.86.

How much money does IDEAYA Biosciences make?

IDEAYA Biosciences has a market capitalization of $1.03 billion and generates $19.54 million in revenue each year. The company earns $-34,490,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does IDEAYA Biosciences have?

IDEAYA Biosciences employs 62 workers across the globe.

What is IDEAYA Biosciences' official website?

The official website for IDEAYA Biosciences is

Where are IDEAYA Biosciences' headquarters?

IDEAYA Biosciences is headquartered at 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080.

How can I contact IDEAYA Biosciences?

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 443-6209 or via email at [email protected].

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.